Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Equivalents (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash & Equivalents for 4 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 479.03% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 479.03% year-over-year, with the annual reading at $6.4 million for FY2025, 479.03% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $6.4 million at bioAffinity Technologies, down from $7.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $13.5 million in Q3 2022, with the low at $444706.0 in Q1 2025.
  • Average Cash & Equivalents over 4 years is $5.1 million, with a median of $3.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 90.36% in 2024, then surged 858.65% in 2025.
  • Over 4 years, Cash & Equivalents stood at $11.4 million in 2022, then crashed by 75.28% to $2.8 million in 2023, then tumbled by 60.83% to $1.1 million in 2024, then surged by 479.03% to $6.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $6.4 million, $7.7 million, and $802835.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.